NCT05841160View on ClinicalTrials.gov

Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

May 7, 2023

Study Completion Date

May 12, 2023

Conditions
QT/QTc
Interventions
DRUG

Ecopipam Hydrochloride

oral tablets

DRUG

Moxifloxacin

oral tablet

DRUG

Placebo

oral tablet

Trial Locations (1)

78744

PPD Austin Phase 1 Clinical Research Unit, Austin

Sponsors

Collaborators (2)

PPD Development, LP
Clario
All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

collaborator

Clario

UNKNOWN

lead

Emalex Biosciences Inc.

INDUSTRY

NCT05841160 - Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization | Biotech Hunter | Biotech Hunter